Enterprise Value

136.2M

Cash

466.4M

Avg Qtr Burn

-43.02M

Short % of Float

15.76%

Insider Ownership

7.35%

Institutional Own.

-

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
RP1 +Opdivo Details
Cancer, Melanoma

BLA

Submission

RP1 + Opdivo Details
Cancer, Non-melanoma skin cancer

Phase 2

Data readout

RP1 + Libtayo (cemiplimab) Details
Cutaneous squamous cell carcinoma, Cancer

Phase 2

Update

RP1 Details
Cancer, Cutaneous squamous cell carcinoma, Kidney transplantation, Liver transplant, Skin cancer

Phase 1/2

Data readout

RP2 + Opdivo Details
Cancer, Uveal melanoma

Phase 1b

Data readout

RP2 +/- Opdivo Details
Solid tumor/s, Cancer, Breast cancer, Head and neck cancer, Lung cancer, Hepatocellular carcinoma

Phase 1

Update

(RP3 & RP2) in comb w/atezolizumab and bevacizumab Details
Cancer, Colorectal cancer , Hepatocellular carcinoma

Failed

Discontinued

RP3 in comb w/std. of care Details
Cancer, Head and neck squamous cell carcinoma

Failed

Discontinued

RP3 +/- Opdivo Details
Solid tumor/s, Cancer, Lung cancer, Head and neck cancer, Breast cancer

Failed

Discontinued